MSME (Udyam registered) Ministry of MSME
- Category
- Small (2023-24)
- Udyam number
- UDYAM-TS-02-0055117
Finoso Pharma Private Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹17.69 Cr
▼ 7% YoY
Net loss · FY 2025
₹8.96 Lakh
Net margin -0.5%
EBITDA · FY 2025
₹2.03 Cr
EBITDA margin 11.5%
Authorised capital
₹3.5 Cr
Registered with MCA
Paid-up capital
₹3.02 Cr
Issued & subscribed
Open charges
₹4.5 Cr
Satisfied ₹2.45 Cr
Company age
17 yrs
Est. 2009
Employees · EPFO
15
Provident fund records
About Finoso Pharma Private Limited
Data last updated:
Finoso Pharma Private Limited is a private limited company based in Hyderabad, Telangana, India, a subsidiary of Vivimed Labs Limited. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 18 August 2009 and has been in existence for over 17 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24231TG2009PTC064774. Its GSTIN is 36AABCF3918L1ZH (Telangana). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹3.5 Cr and a paid-up capital of ₹3.02 Cr. It is led by directors including Aparna Bidarkar and Kunapareddy Devi Prasad.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Sp Biotech Park – Phase – I Block – I Turkapally Shameerpet Mandal, Hyderabad, Telangana, India – 500078.
As per the financials filed for FY 2025, the company reported a revenue of ₹17.69 Cr, a decline of 7% compared to the previous year. For the same year it recorded a net loss of ₹8.96 Lakh (net margin -0.5%) and EBITDA of ₹2.03 Cr (EBITDA margin 11.5%). Revenue has declined at a compounded annual rate (CAGR) of 7% over three years and 6% over five years.
The company has about 15 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Finoso Pharma and Vivimed Labs. As per MCA filings, the company has open charges of ₹4.5 Cr and satisfied charges of ₹2.45 Cr on record. The company has 6 deals on record (4 secondary share transfers, 2 funding rounds), with disclosed funding of ₹1.51 Cr; the latest was in December 2017. Its 7 peer companies in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development) are compared by revenue, 3 larger and 4 smaller; the largest is Vipragen Biosciences Private Limited with revenue of ₹18.35 Cr.
Finoso Pharma Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0055117). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website finoso.com.
Company details
CIN U24231TG2009PTC064774
Registration Number 064774
Incorporation Date 18 August 2009
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Vivimed Labs Limited
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-TS-02-0055117
CIN history
Finoso Pharma has one previous CIN (Corporate Identification Number): U24231AP2009PTC064774. The current CIN is U24231TG2009PTC064774, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231TG2009PTC064774 | Current |
| U24231AP2009PTC064774 | Previous |
Key People
Aparna Bidarkar Director Kunapareddy Devi Prasad Additional Director Phaninder Nath Peta Sonti Additional Director Recognitions & Rankings of Finoso Pharma
Contact details
Finoso Pharma Private Limited's registered office is in Hyderabad, Telangana. Its website is finoso.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressSp Biotech Park – Phase – I Block – I Turkapally Shameerpet Mandal, Hyderabad, Telangana, India – 500078
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Finoso Pharma Private Limited, buy the company report.
Comprehensive company report
Finoso Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Finoso Pharma operates two associated brands: Finoso Pharma and Vivimed Labs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Offers pharmaceutical formulation research, development, manufacturing, and business services. | finoso.com | |
| Active pharmaceutical ingredients, formulations, and specialty chemicals are manufactured. | vivimedlabs.com |
Business activity
The main business activity of Finoso Pharma is professional, scientific and technical. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Finoso Pharma Private Limited, buy the company report.
Financials of Finoso Pharma Private Limited
FY 2025 filings availableFinoso Pharma Private Limited reported revenue of ₹17.69 Cr (down 7% YoY) for FY 2025.
Revenue · FY 2025
₹17.69 Cr ▼ 7%
Net loss · FY 2025
₹8.96 Lakh margin -0.5%
EBITDA · FY 2025
₹2.03 Cr margin 11.5%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 7%
3 years · compounded
▼ 7%
5 years · compounded
▼ 6%
EBITDA CAGR growth
1 year
▲ 228%
3 years · compounded
▲ 6%
5 years · compounded
▼ 12%
Revenue has declined at a compounded annual rate (CAGR) of 6% over five years, including a 7% fall in the latest year. EBITDA rose 228% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2.03 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹8.96 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 11.5% | ||||
| Net Profit Margin | -0.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Finoso Pharma Private Limited, buy the company report.
Board of directors of Finoso Pharma Private Limited
Finoso Pharma has 3 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Aparna Bidarkar Also directs: Lattice Projex Private Limited | Director | 05 Jun 2025 | 1 Years 4 Months | Current |
| Kunapareddy Devi Prasad | Additional Director | 08 Mar 2024 | 2 Years 7 Months | Current |
| Phaninder Nath Peta Sonti | Additional Director | 16 Jul 2025 | 1 Years 3 Months | Current |
Peer comparison
Finoso Pharma Private Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Vipragen Biosciences Private Limited | ₹18.35 Cr (FY 2025) | 46.0% | Mysore, Karnataka, India | |||
| Vivancemed India Private Limited | ₹18.19 Cr (FY 2024) | 20.0% | Bangalore, Karnataka, India | |||
| Monolom India Pharma Private Limited | ₹18.17 Cr (FY 2025) | -1.0% | Pune, Maharashtra, India | |||
| Finoso Pharma Private Limitedthis company | ₹17.69 Cr (FY 2025) | -₹8.96 Lakh | -0.5% | -7.0% | 15 | Hyderabad, Telangana, India |
| Semler Research Center Private Limited | ₹17.66 Cr (FY 2025) | 926.0% | Bengaluru, Karnataka, India | |||
| Suven Life Sciences Limited | ₹17.55 Cr (FY 2025) | -47.0% | Hyderabad, Telangana, India | |||
| Sravathi Advance Process Technologies Private Limited | ₹17.29 Cr (FY 2025) | 40.0% | Bangalore, Karnataka, India | |||
| Clinsync Clinical Research Private Limited | ₹15.75 Cr (FY 2025) | -38.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Finoso Pharma Private Limited, buy the company report.
Auditor
Finoso Pharma Private Limited is audited by GPHK & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| GPHK & ASSOCIATES | FY 2023 | 008053S |
Shareholding
The shareholding of Finoso Pharma Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Finoso Pharma Private Limited, buy the company report.
Charges & borrowings
Open charges
₹4.5 Cr
Satisfied charges
₹2.45 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 31 Dec 2014 | 10549154 | State Bank of India | ₹4.5 Cr | Open | |
| 28 Oct 2009 | 10186661 | State Bank of India | ₹2.45 Cr | Satisfied |
To see the full charge records of Finoso Pharma Private Limited, buy the company report.
Total charge records: 2 View all charges
Deals & funding
Finoso Pharma Private Limited has 6 deals on record (4 secondary share transfers, 2 funding rounds), with disclosed funding of ₹1.51 Cr; the latest was in December 2017.
Total deals
6
Secondary share transfers
4
Funding rounds
2
Disclosed funding
₹1.51 Cr
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2017 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2014 | Secondary share transfer | Undisclosed | Buyer: Vivimed Labs Limited , an individual Seller: 4 individuals |
| Mar 2011 | Funding round | ₹11.2 Lakh | Investors: an individual |
| Mar 2011 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Mar 2010 | Funding round | ₹1.4 Cr | Investors: Sirak Pharmaceuticals Private Limited , 3 individuals |
To see the full deal history of Finoso Pharma Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Finoso Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Finoso Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Finoso Pharma Private Limited has a workforce of 15 employees on its EPFO records as of Aug 07, 2025, across 1 active EPFO establishment.
Employee count
15
Active EPFO establishments
1
Employee growth
25%
GST
Finoso Pharma has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AABCF3918L1ZH | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Finoso Pharma Private Limited, buy the company report.
Recent activity
Finoso Pharma Private Limited has 13 board changes on record since 2010: 3 appointments and 10 cessations. The latest: Phaninder Nath Peta Sonti was appointed as Additional Director on 16 Jul 2025.
AGM
Finoso Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Appointed
Phaninder Nath Peta Sonti was appointed as Additional Director.
Appointed
Aparna Bidarkar was appointed as Director.
Filing
Finoso Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Appointed
Kunapareddy Devi Prasad was appointed as Additional Director.
Ceased
Dillip Kumar Jena ceased to be Additional Director.
Ceased
Ramakanta Tripathy ceased to be Additional Director.
Ceased
Santosh Varalwar ceased to be Director.
Ceased
Kirankumar Subbaraja Madallapalli ceased to be Additional Director.
Ceased
Ramesh Challa ceased to be Director.
Charges
A charge with State Bank Of India of Rs. 4.50 Cr registered on 31 Dec 2014 with Charge ID 10549154 was modified on 08 Nov 2017.
Ceased
Phanindernath Petasonti ceased to be Director.
8 earlier events are in the company report.
Frequently asked questions
Finoso Pharma is an active private limited company based in Hyderabad, Telangana, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 18 August 2009 (17+ years old) and is registered under CIN U24231TG2009PTC064774.
Finoso Pharma has 3 current directors:
- Aparna Bidarkar - Director
- Kunapareddy Devi Prasad - Additional Director
- Phaninder Nath Peta Sonti - Additional Director
The latest financial statements of Finoso Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Finoso Pharma is 36AABCF3918L1ZH, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Finoso Pharma is U24231TG2009PTC064774. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Finoso Pharma was incorporated on 18 August 2009, making it 17+ years old. It is registered with the Registrar of Companies, Hyderabad.
Finoso Pharma has 6 deals on record (4 secondary share transfers, 2 funding rounds), with disclosed funding of ₹1.51 Cr; the latest was in December 2017.
The peers of Finoso Pharma by revenue are Vipragen Biosciences Private Limited, Vivancemed India Private Limited, Monolom India Pharma Private Limited, Semler Research Center Private Limited, Suven Life Sciences Limited and 2 more, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).
Phaninder Nath Peta Sonti was appointed as Additional Director on 16 Jul 2025. Aparna Bidarkar was appointed as Director on 05 Jun 2025. Kunapareddy Devi Prasad was appointed as Additional Director on 08 Mar 2024. Finoso Pharma has 13 board changes on record in total.
Yes, Finoso Pharma is registered as a small enterprise under Udyam registration (number: UDYAM-TS-02-0055117).
Finoso Pharma can be reached through the website finoso.com. Its registered office is in Hyderabad, Telangana, India.